Javier A. Adachi, Herbert L. DuPont. Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders. Clinical Infectious Diseases, Volume 42, Issue 4, 15 February 2006, Pages 541–547, https://doi.org/10.1086/499950.
Gathe JC Jr, Mayberry C, Clemmons J, et al. Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. J Acquir Immune Defic Syndr. 2008; 48:363–364. [PubMed: 18580340]
Avelar Rodriguez D, Ryan PM, Toro Monjaraz EM, Ramirez Mayans JA, Quigley EM. Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review. Front Pediatr. 2019 Sep 4;7:363. doi: 10.3389/fped.2019.00363. PMID: 31552207; PMCID: PMC6737284.
Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol 2018; 24(21): 2211-2235 [PMID: 29881232 DOI: 10.3748/wjg.v24.i21.2211]
Bruzzese E, Pesce M, Sarnelli G, Guarino A. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):753-760. doi: 10.1080/17425255.2018.1488964. Epub 2018 Jun 22. PMID: 29897844.
Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):400-4. doi: 10.1097/MPG.0b013e3181a0d269. PMID: 19668011.
Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 Suppl. 1: 36-66
Ladevaia MD, Prete AD, Cesaro C, Gaeta L, Zulli C, Loguercio C. Rifaximin in the treatment of hepatic encephalopathy. Hepat Med. 2011 Dec 22;3:109-17. doi: 10.2147/HMER.S11988. PMID: 24367227; PMCID: PMC3846583.
